What You Should Know:
– Otsuka America, Inc. (OAI) today announced the formation of Otsuka Precision Health (OPH), a new subsidiary dedicated to transforming patient care through innovative digital solutions and a data-driven approach.
– OPH will leverage cutting-edge technology, including artificial intelligence (AI) and digital therapeutics, to personalize patient care journeys across various conditions, from mental health to nephrology.
A Patient-Centric Approach Powered by Data
OPH prioritizes the patient experience, aiming to achieve better outcomes by tailoring interventions to individual needs. This data-driven approach stands in contrast to traditional pharmaceutical models and seeks to unlock new possibilities for improved patient journeys.
Rejoyn™ Paves the Way for Personalized Mental Health Care
The recent FDA clearance of Rejoyn™, the first prescription digital therapeutic for major depressive disorder (MDD), exemplifies OPH’s commitment to bringing groundbreaking technologies to market. Rejoyn™ serves as a testament to the potential of digital therapeutics in improving patient experiences.
Combining Pharmaceutical Expertise with Digital Innovation
By combining the proven scientific rigor of Otsuka Pharmaceutical with a data-centric focus on patient experience, OPH has a unique advantage. This approach allows for faster development and commercialization of promising healthcare innovations.
Deepening Otsuka’s Commitment to Technology
Otsuka’s investment in OPH underscores its unwavering belief in the power of technology to improve patient lives and empower healthcare teams. OPH aims to:
- Personalize care: Tailor interventions to individual patient needs and journeys.
- Increase access: Unlock doors to healthcare solutions for a wider range of patients.
- Unify the healthcare experience: Bridge the gaps between different aspects of care delivery for a more seamless experience.
Otsuka Precision Health’s current focus areas include:
- Developing and delivering prescription digital therapeutics like Rejoyn™.
- Creating innovative technological solutions to address individual health needs.
- Providing non-promotional patient support services.
“Changes are needed to realize the potential of technology in health, and we’re ready to boldly address the barriers patients face in receiving care by taking a fundamentally new approach,” said Sanket Shah, president of OPH. “This Company will allow us to build on our commitment to the digital and technology space and continue building momentum with products such as, Rejoyn™, in a way that traditional pharmaceutical companies have not been able to explore.”
